Insights

Immuno-Reset Platform Revolo Biotherapeutics focuses on immune system resetting therapies with disease-agnostic mechanisms, presenting a scalable platform for addressing multiple autoimmune and allergic diseases. This suggests opportunities to engage across multiple indications and potential collaborations or licensing discussions for novel targets.

Lead Program Spotlight Lead candidates IRL201104 (‘1104) and 1805 target eosinophilic and inflammatory conditions, with current clinical development in EoE, RA, and non-infectious uveitis. This creates entry points for conversations with rheumatology, allergy, and ophthalmology stakeholders, as well as potential investigator-initiated studies and payer discussions for expanded indications.

Clinical Momentum Regular conference outreach including AAAAI and WAO joint congress presentations indicates active engagement with clinical investigators and KOLs. Sales teams can leverage these events to secure early-adopter sites, build relationships with participating centers, and accelerate site onboarding for trials or collaborations.

Strategic Partnerships Past collaboration with Northway Biotech for manufacturing indicates openness to CDMO partnerships and external manufacturing support. This may translate into opportunities to offer co-development, manufacturing collaborations, or supply chain partnerships to support broader trial programs.

Financial and Size Signals With a modest employee base and revenue in the mid-range, plus funding of $52M, Revolo appears to be in a growth phase likely seeking strategic partnerships, additional funding rounds, or deal-making with contract manufacturers, CROs, or specialty pharma to scale development and commercialization plans.

Similar companies to Revolo Biotherapeutics

Revolo Biotherapeutics Tech Stack

Revolo Biotherapeutics uses 8 technology products and services including iCIMS, Squarespace, WordPress, and more. Explore Revolo Biotherapeutics's tech stack below.

Revolo Biotherapeutics's Email Address Formats

Revolo Biotherapeutics uses at least 2 email formats:
Revolo Biotherapeutics Email FormatsExamplePercentage
FLast@revolobio.comJDoe@revolobio.com
96%
FMiddleLast@revolobio.comJMichaelDoe@revolobio.com
4%

Frequently Asked Questions

What is Revolo Biotherapeutics's official website and social media links?

Minus sign iconPlus sign icon
Revolo Biotherapeutics's official website is revolobio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Revolo Biotherapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Revolo Biotherapeutics's annual revenue is estimated to be $1M - $10M.

What is Revolo Biotherapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Revolo Biotherapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Revolo Biotherapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Revolo Biotherapeutics has approximately 17 employees across 3 continents, including North America, Europe and Asia. Key team members include Chief Medical Officer: K. B., Vice President Discovery And Translational Science: J. D. A. and Director, Human Resources And Senior Executive Administration: C. V. Explore Revolo Biotherapeutics's employee directory with LeadIQ.

What industry does Revolo Biotherapeutics belong to?

Minus sign iconPlus sign icon
Revolo Biotherapeutics operates in the Biotechnology Research industry.

What technology does Revolo Biotherapeutics use?

Minus sign iconPlus sign icon
Revolo Biotherapeutics's tech stack includes iCIMS, Squarespace, WordPress, Barracuda Email Protection, jQuery, Swiper, DocuSign and Piwik PRO Core.

What is Revolo Biotherapeutics's email format?

Minus sign iconPlus sign icon
Revolo Biotherapeutics's email format typically follows the pattern of FLast@revolobio.com. Find more Revolo Biotherapeutics email formats with LeadIQ.

How much funding has Revolo Biotherapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Revolo Biotherapeutics has raised $52M in funding. The last funding round occurred on Sep 21, 2020 for $52M.

When was Revolo Biotherapeutics founded?

Minus sign iconPlus sign icon
Revolo Biotherapeutics was founded in 2011.
Revolo Biotherapeutics logo

Revolo Biotherapeutics

Biotechnology ResearchMaryland, United States11-50 Employees

Revolo Biotherapeutics is a biotechnology research company focused on developing therapies that aim to reset the immune system to achieve long-term remission for autoimmune and allergic diseases. Its lead candidates, a protein and a peptide, target the chronic pro-inflammatory immune response underlying conditions such as rheumatoid arthritis, non-infectious uveitis, eosinophilic esophagitis, and other allergic diseases, with the potential to serve as a disease-agnostic platform for immune-mediated disorders. Headquartered in Gaithersburg, Maryland, the company operates within the biotechnology research sector and collaborates with contract manufacturing and industry partners to advance its clinical programs. Recent activities include presenting at major allergy and immunology conferences, illustrating ongoing engagement with the scientific community and progression of its clinical development efforts.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
11-50

Section iconFunding & Financials

  • $52M

    Revolo Biotherapeutics has raised a total of $52M of funding over 2 rounds. Their latest funding round was raised on Sep 21, 2020 in the amount of $52M as a Series B.

  • $1M - $10M

    Revolo Biotherapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.